Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 141

1.

P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries.

Zeymer U, Widimsky P, Danchin N, Lettino M, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, De Luca L, Dörler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Lüscher TF, Matter CM, Montalescot G, Radovanovic D, Sendón JL, Tousek P, Weidinger F, Weston CF, Zaman A, Andell P, Li J, Jukema JW; PIRAEUS group.

Eur Heart J Cardiovasc Pharmacother. 2016 Mar 2. pii: pvw005. [Epub ahead of print]

PMID:
27533946
Free Article
2.

Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations.

Jukema JW, Lettino M, Widimský P, Danchin N, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, De Luca L, Dörler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Lüscher TF, Matter CM, Montalescot G, Radovanovic D, Lopez-Sendón J, Tousek P, Weidinger F, Weston CF, Zaman A, Zeymer U; PIRAEUS group.

Eur Heart J Cardiovasc Pharmacother. 2015 Oct;1(4):232-44. doi: 10.1093/ehjcvp/pvv024. Epub 2015 May 12.

PMID:
27532447
Free Article
3.

Use of prasugrel in the setting of clopidogrel hypersensitivity: Case report and systematic review of the literature.

Siu H, Kaliyadan A, Fischman DL, Nardone E, Poll D, Savage MP.

Platelets. 2016 Aug 5:1-4. [Epub ahead of print]

PMID:
27494368
4.

Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials.

Fanari Z, Malodiya A, Weiss SA, Hammami S, Kolm P, Weintraub WS.

Cardiovasc Revasc Med. 2016 Jul 20. pii: S1553-8389(16)30193-2. doi: 10.1016/j.carrev.2016.07.006. [Epub ahead of print]

PMID:
27477306
5.

State of the art: Oral antiplatelet therapy.

Gurbel PA, Myat A, Kubica J, Tantry US.

JRSM Cardiovasc Dis. 2016 Jun 1;5:2048004016652514. doi: 10.1177/2048004016652514. eCollection 2016 Jan-Dec. Review.

6.

P2Y12 receptor antagonists: which one to choose? A systematic review and meta-analysis.

Briasoulis A, Telila T, Palla M, Siasos G, Tousoulis D.

Curr Pharm Des. 2016 Jun 8. [Epub ahead of print]

PMID:
27290917
7.

Extended duration dual antiplatelet therapy in patients with myocardial infarction: A study-level meta-analysis of controlled randomized trials.

Patti G, Cavallari I.

Am Heart J. 2016 Jun;176:36-43. doi: 10.1016/j.ahj.2016.03.005. Epub 2016 Mar 21.

PMID:
27264218
8.

Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review.

Khan N, Cox AR, Cotton JM.

Thromb Res. 2016 Jul;143:141-8. doi: 10.1016/j.thromres.2016.05.019. Epub 2016 May 25. Review.

PMID:
27259210
9.

Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.

Rafique AM, Nayyar P, Wang TY, Mehran R, Baber U, Berger PB, Tobis J, Currier J, Dave RH, Henry TD.

JACC Cardiovasc Interv. 2016 May 23;9(10):1036-46. doi: 10.1016/j.jcin.2016.02.013.

PMID:
27198684
10.

Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome.

Rossington JA, Brown OI, Hoye A.

Open Heart. 2016 Feb 26;3(1):e000296. doi: 10.1136/openhrt-2015-000296. eCollection 2016.

11.

Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.

Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA, Radaelli F, Knight E, Gralnek IM, Hassan C, Dumonceau JM.

Gut. 2016 Mar;65(3):374-89. doi: 10.1136/gutjnl-2015-311110.

12.

Developing drugs for use before, during and soon after percutaneous coronary intervention.

Gargiulo G, Moschovitis A, Windecker S, Valgimigli M.

Expert Opin Pharmacother. 2016;17(6):803-18. doi: 10.1517/14656566.2016.1145666. Epub 2016 Mar 3.

PMID:
26800365
13.

Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: A Study-level Meta-analysis From 15 Studies.

Patti G, Ricottini E, De Luca L, Cavallari I.

J Cardiovasc Pharmacol. 2016 Apr;67(4):336-43. doi: 10.1097/FJC.0000000000000359.

PMID:
26771153
14.

An evidence summary of the management of the care of patients taking novel oral antiplatelet drugs undergoing dental surgery.

Johnston S.

J Am Dent Assoc. 2016 Apr;147(4):271-7. doi: 10.1016/j.adaj.2015.11.007. Epub 2015 Dec 19.

PMID:
26712308
15.

PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.

Mega JL, Close SL, Wiviott SD, Man M, Duvvuru S, Walker JR, Sundseth SS, Collet JP, Delaney JT, Hulot JS, Murphy SA, Paré G, Price MJ, Sibbing D, Simon T, Trenk D, Antman EM, Sabatine MS.

J Thromb Thrombolysis. 2016 Apr;41(3):374-83. doi: 10.1007/s11239-015-1264-9.

PMID:
26573179
16.

Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials.

Verma S, Goodman SG, Mehta SR, Latter DA, Ruel M, Gupta M, Yanagawa B, Al-Omran M, Gupta N, Teoh H, Friedrich JO.

BMC Surg. 2015 Oct 14;15:112. doi: 10.1186/s12893-015-0096-z. Review.

17.
18.

Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.

Gan XD, Wei BZ, Fang D, Fang Q, Li KY, Ding SL, Peng S, Wan J.

Curr Med Res Opin. 2015 Dec;31(12):2313-23. doi: 10.1185/03007995.2015.1098600. Epub 2015 Nov 4. Review.

PMID:
26402735
19.

Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.

Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E, Bhatt DL.

Eur Heart J. 2016 Jan 21;37(4):390-9. doi: 10.1093/eurheartj/ehv443. Epub 2015 Aug 31.

PMID:
26324537
20.

Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review.

Bouatou Y, Samer CF, Fontana P, Daali Y, Desmeules J.

Curr Drug Metab. 2015;16(2):97-104. Review.

PMID:
26179606
Items per page

Supplemental Content

Loading ...
Write to the Help Desk